Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology – what we know and what we do not know from randomized controlled trials

Abstract Background Biologic disease modifying antirheumatic drugs (bDMARDs) and Janus Kinase (JAK) inhibitors are prescribed in adult and paediatric rheumatology. Due to age-dependent changes, disease course, and pharmacokinetic processes paediatric patients with inflammatory rheumatic diseases (Pi...

Full description

Bibliographic Details

Published in:	Pediatric Rheumatology Online Journal
Main Authors:	Tatjana Welzel, Carolyn Winskill, Nancy Zhang, Andreas Woerner, Marc Pfister
Format:	Article
Language:	English
Published:	BMC 2021-03-01
Subjects:	Randomized controlled trials Paediatric rheumatology Monoclonal antibodies Efficacy Safety Pharmacokinetics
Online Access:	https://doi.org/10.1186/s12969-021-00514-4